연구
연구업적
최근 5년 연구업적 현황
| 연도 | 2025년 | 2024년 | 2023년 | 2022년 | 2021년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 196편 | 179편 | 173편 | 163편 | 184편 |
| 공동 | 132편 | 147편 | 120편 | 115편 | 136편 | |
| 합계 | 328편 | 326편 | 293편 | 278편 | 320편 | |
3405. Association between body fat decrease during the first year after diagnosis and the prognosis of idiopathic pulmonary fibrosis: CT-based body composition analysis.
Lee JY, Yoon SH, Goo JM, Park J, Lee JH
Respir Res. 2024 Feb 28;25(1):103.
Link
3404. Usual Interstitial Pneumonia: Associations With Complications After Percutaneous Transthoracic Needle Lung Biopsy.
Park J, Lee JH, Hong W, Hwang EJ, Yoon SH, Goo JM, Park CM.
AJR Am J Roentgenol. 2024 Feb;222(2):e2329938.
Link
3403. Defining and tracing subtypes of patient-derived xenograft models in pancreatic ductal adenocarcinom
Hyun S, Han Y, Moon JY, Suh YA, Yun WG, Kwon W, Lee JE, Kim D, Ku JL, Jang JY, Park D
Cancer Commun (Lond). 2024 Aug;44(8):921-925.
Link
3402. Antiproliferative Activity of Piceamycin by Regulating Alpha-Actinin-4 in Gemcitabine-Resistant Pancreatic Cancer Cells
Lee JH, Choi JH, Lee KM, Lee MW, Ku JL, Oh DC, Shin YH, Kim DH, Cho IR, Paik WH, Ryu JK, Kim YT, Lee SH, Lee SK
Biomol Ther (Seoul). 2024 Jan 1;32(1):123-135
Link
3401. Ruxolitinib for pediatric patients with treatment-naive and steroid-refractory acute graft-versus-host disease (REACH4).
Locatelli F, Kang HJ, Bruno B, Gandemer V, Rialland-Battisti F, Faraci M, Takahashi Y, Koh K, Bittencourt H, Cleary G, Rosko C, Li X, St Pierre A, Prahallad AC, Diaz-de-Heredia C.
Blood. 2024 Nov Nov 14;144(20):2095-2106.
Link
3400. Dual inhibition of sirtuins 1 and 2: reprogramming metabolic energy dynamics in chronic myeloid leukemia as an immunogenic anticancer strategy.
Schnekenburger M, Lorant A, Gajulapalli SR, Rajora R, Lee JY, Mazumder A, Yang H, Christov C, Kang HJ, Pirotte B, Diederich M.
Cancer Commun (Lond) 2024 Aug 44(8):915-920.
Link
3399. Ruxolitinib in treatment-naive or corticosteroid-refractory paediatric patients with chronic graft-versus-host disease (REACH5): interim analysis of a single-arm, multicentre, phase 2 study.
Locatelli F, Antmen B, Kang HJ, Koh K, Takahashi Y, Kupesiz A, Dias Matos MGA, Chopra Y, Bhat S, Im HJ, Gungor T, Lu MY, Stefanelli T, Rosko C, St Pierre A, Burock K, Smith Y, Sinclair K, Diaz-de-Heredia C.
Lancet Haematol. 2024 Aug 1(8):e580-e592.
Link
3398. NTRK-fused central nervous system tumours: clinicopathological and genetic insights and response to TRK inhibitors.
Kim EE, Park CK, Kim SK, Phi JH, Paek SH, Choi JY, Kang HJ, Lee JH, Won JK, Yun H, Park SH.
Acta Neuropathol Commun 2024 Jul 12(1):118.
Link
3397. Phase 3 randomized trial of mavorixafor, CXCR4 antagonist, in WHIM syndrome.
Badolato R, Alsina L, Azar A, Bertrand Y, Bolyard AA, Dale DC, Deya-Martinez A, Dickerson KE, Ezra N, Hasle H, Kang HJ, Kiani-Alikhan S, Kuijpers TW, Kulagin A, Langguth D, Levin C, Neth O, Olbrich P, Peake J, Rodina Y, Rutten CE, Shcherbina A, Tarrant TK, Vossen MG, Wysocki CA, Belschner A, Bridger GJ, Chen K, Dubuc S, Hu Y, Jiang H, Li S, MacLeod R, Stewart M, Taveras AG, Yan T, Donadieu J.
Blood. 2024 Jul 144(1):35-45.
Link
3396. Antileukemic potential of methylated indolequinone MAC681 through immunogenic necroptosis and PARP1 degradation.
Orlikova-Boyer B, Lorant A, Gajulapalli SR, Cerella C, Schnekenburger M, Lee JY, Paik JY, Lee Y, Siegel D, Ross D, Han BW, Nguyen TKY, Christov C, Kang HJ, Dicato M, Diederich M.
Biomark Res. 2024 May 12(1):47.
Link